MIRA INFORM REPORT

 

 

 

Report Date :

08.12.2008

 

IDENTIFICATION DETAILS

 

Name :

CYANO PHARMA PRIVATE LIMITED

 

 

Registered Office :

115 – C, Industrial Estate (Pologround), Indore – 452007, Madhya Pradesh

 

 

Country :

India

 

 

Financials (as on) :

31.03.2007

 

 

Date of Incorporation :

29.02.2008

 

 

Com. Reg. No.:

10-14072

 

 

CIN No.:

[Company Identification No.]

U24232MP2000PTC014072

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

BPLC01379A

 

 

PAN No.:

[Permanent Account No.]

AACCC2242F

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufacturer and Exporter of Pharmaceuticals Products

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

 

Maximum Credit Limit :

USD 90000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is a well – established and reputed company having satisfactory track. Trade relations are fair. Business is active. Payments are reported as usually made as per commitments.

 

The company can be considered good for normal business dealings.

 

 

INFORMATION PARTED BY

 

Name :

Mr. Smitesh Shah

Designation :

Vice President

Contact No.:

91-9302522453

Date :

06.12.2008

 

 

LOCATIONS

 

Registered Office/ Factory :

115 – C, Industrial Estate (Pologround), Indore – 452007, Madhya Pradesh, India

Tel. No.:

91-731-2422453/ 2421274

Mobile No.:

91-9302522453

Fax No.:

91-731-2420926

E-Mail :

cyano2004@hotmail.com

cyano@cyanopharmagroup.com
biofil@cyanopharmagroup.com
biofilhealth@cyanopharmagroup.com

formoplast@cyanopharmagroup.com
info@cyanopharmagroup.com

cyano@biofilgroup.com

biofil@sancharnet.in

Website :

http://www.cyanopharmagroup.com

http://www.biofilgroup.com

Area :

28000 sq. ft.

Location :

Leased

 

 

DIRECTORS

 

Name :

Mr. Sandeep Shah

Designation :

Director

Address :

204, Chetak Vihar, New Palasiya, Indore – 452001, Madhya Pradesh, India

Date of Birth/Age :

07.06.1963

Qualification :

M. Com

Date of Appointment :

29.02.2000

 

 

Name :

Mr. Pragnesh Shah

Designation :

Director

Address :

202, Chetak Vihar, New Palasiya, Indore – 452001, Madhya Pradesh, India

Date of Birth/Age :

11.05.1965

Qualification : 

BSC, MA, LLB

Date of Appointment :

28.11.2003

 

 

KEY EXECUTIVES

 

Name :

Mr. Smitesh Shah

Designation :

Vice President

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

(As on 29.09.2007)

Names of Shareholders

 

No. of Shares

 

 

 

Smitesh Shah

 

17535

Smitesh Shah (HUF)

 

3530

Kiran Shah

 

7950

Meena Shah

 

7950

Varsha Shah

 

6685

Ramesh Shah

 

2430

Trupti Shah

 

7530

Sandeep Shah

 

13790

Sandeep Shah (HUF)

 

3060

Ketan Shah

 

12985

Ketan Shah (HUF)

 

2905

Pragnesh Shah

 

14370

Sanalal Shah

 

147870

Ramesh Shah (HUF)

 

3370

Mid India Pharmaceuticals Limited

 

10270

Kapsulabs

 

6475

Bloom Field Equity (Private) Limited

 

1000

Cyano Finance and Sales (Private) Limited

 

17880

 

 

 

Total

 

287585

 

(As on 30.09.2008)

Category

 

Percentage

 

 

 

Bodies Corporate

 

10.13

Directors or relatives of directors

 

89.87

 

 

 

Total

 

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer and Exporter of Pharmaceuticals Products

 

 

Products :

  • Antibacterials 
  • Antiepieptics 
  • Antacids 
  • Analgesics/Antipyretics 
  • Antimalarials 
  • Antispasmodics 
  • Antidiorrheal / Antidysentry / Anti Amoebics 
  • Antipsycotics 
  • Anthelmentics 
  • Anti Asthmatic / Bronchodilators 
  • Diuretics 
  • Antihistaminics 
  • Cold/Flue/Allergy/Fever 
  • Cough Expectorant 
  • Tranquilizer / Hypnotics 
  • Anti Inflammatory/ Analgesic/Antipyretics 
  • Anti Inflammatory Steroids 
  • Anti tuburcular 
  • Antifungal 
  • Multivitamin & Tonics 
  • Scabicides 
  • First-Aid And Dental Products 
  • Antiseptic solution/powders 
  • Ear & Nasal Drops 
  • Water Purifying Formulation 
  • Miscellaneous & Ayurvedic 

 

 

Exports :

 

Products :

Pharmaceuticals Products

Countries :

  • African Countries
  • Yemen
  • Keneya
  • Tanzania
  • Turkey
  • Mauritius
  • United Arab Emirates
  • Nigeria
  • Germany
  • Liberia

 

 

Imports :

 

Products :

Raw Materials

Countries :

China

 

 

Terms :

 

Selling :

Credit (90 days)

 

 

Purchasing :

Credit (30-60 days)

 

 

GENERAL INFORMATION

 

Customers :

  • Government Suppliers
  • Army
  • Pharmaceutical Industry

 

 

No. of Employees :

135 (Office – 10 and Factory – 125)

 

 

Bankers :

  • State Bank of Indore

Industrial Estate Branch, Pologround, Indore - 452016, Madhya Pradesh, India

 

 

Facilities :

CC – Rs.0.125 Million

 

Secured Loans

31.03.2007

(Rs. In Millions)

 

 

State Bank of Indore

 

Working Capital Loan

4.656

Book Debts

1.929

EPC Loan

1.500

UBD/DBP Loan

-

(Secured by first charge-against inventories, debtors and personal Guarantee of all the director)

 

Total

8.085

 

Unsecured Loans

31.03.2007

(Rs. In Millions)

 

 

From Director

0.168

From Others

7.816

From Shareholders

4.136

Total

12.120

 

 

 

Banking Relations :

Satisfactory

 

 

Auditors :

 

Name :

Sethiya Khandelwal and Company

Chartered Accountant

Address :

209, Manas Bhavan Extension, 11 R N T Marg, Indore – 452001, Madhya Pradesh, India 

Tel No.:

91-731-4050947/ 2594727

Fax No.:

91-731-2516602

 

 

Group Company :

  • Cyano Pharma (Private) Limited
  • Biofil Chemicals and Pharmaceuticals Limited
  • Biofil Healthcare (Private) Limited
  • Formoplast (Private) Limited, Indore

(Manufacturer of Plastic)

 

 

CAPITAL STRUCTURE

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

300000

Equity Shares

Rs.10/- each

Rs.3.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

287585

Equity Shares

Rs.10/- each

Rs.2.876 Millions

 

 

 

 

 


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2007

31.03.2006

31.03.2005

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

2.876

2.876

2.426

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

14.408

11.935

7.379

4] (Accumulated Losses)

0.000

0.000

(0.005)

NETWORTH

17.284

14.811

9.800

LOAN FUNDS

 

 

 

1] Secured Loans

8.085

8.906

10.376

2] Unsecured Loans

12.120

10.234

9.205

TOTAL BORROWING

20.205

19.140

19.581

DEFERRED TAX LIABILITIES

0.617

0.350

0.035

 

 

 

 

TOTAL

38.106

34.301

29.416

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

15.973

12.519

11.278

Capital work-in-progress

0.000

0.000

0.000

 

 

 

 

INVESTMENT

0.000

0.000

0.000

DEFERREX TAX ASSETS

0.000

0.000

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

10.332

11.183

9.331

 

Sundry Debtors

56.986

32.818

20.176

 

Cash & Bank Balances

0.916

0.373

1.136

 

Other Current Assets

0.000

0.000

0.000

 

Loans & Advances

3.464

0.734

0.810

Total Current Assets

71.698

45.108

31.453

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Current Liabilities

45.334

20.139

12.656

 

Provisions

4.231

3.187

0.659

Total Current Liabilities

49.565

23.326

13.315

Net Current Assets

22.133

21.782

18.138

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

38.106

34.301

29.416

 


PROFIT & LOSS ACCOUNT

 

PARTICULARS

 

31.03.2007

31.03.2006

31.03.2005

 

 

 

 

Sales Turnover

121.507

69.824

NA

Other Income

0.289

0.397

NA

Total Income

121.796

70.221

NA

 

 

 

 

Profit/(Loss) Before Tax

3.131

0.930

1.270

Provision for Taxation

0.655

0.417

0.000

Profit/(Loss) After Tax

2.476

0.513

1.270

 

 

 

 

Expenditures :

 

 

 

 

Manufacturing Expenses

6.401

4.204

 

Administrative Expenses

4.478

2.469

 

 

Selling and Distributors Expenses

18.208

11.044

 

 

Purchases made for re-sale

85.626

50.707

 

 

Increase/(Decrease) in Finished Goods

0.851

(1.852)

NA

 

Interest

2.248

1.935

 

 

Depreciation & Amortization

0.854

0.785

 

 

Other Expenditure

0.000

0.000

 

Total Expenditure

118.665

69.291

 

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2007

31.03.2006

31.03.2005

PAT / Total Income

(%)

2.03

0.73

NA

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

2.58

1.33

NA

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

3.57

1.61

2.97

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.18

0.06

0.13

 

 

 

 

 

Debt Equity Ratio

(Total Liability/Networth)

 

4.04

2.87

3.36

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.45

1.93

2.36

 

 

LOCAL AGENCY FURTHER INFORMATION

 

 

Trade Reference:

 

 

 

 

Working Results:

 

The company has earned net profit of Rs.3.131 Millions against the profit Rs0.930 Millions which has been carried to the balance sheet and directors are hopeful to get better results in the current year.

 

 

Form 8:

 

Corporate identity number of the company

U24232MP2000PTC014072

Name of the company

CYANO PHARMA PRIVATE LIMITED

Address of the registered office or of the principal place of  business in India of the company

115 – C, Industrial Estate (Pologround), Indore – 452007, Madhya Pradesh, India

This form is for

Modification of charge

Type of charge

Immovable Property

Book Debts

Movable Property

Floating Charge

Particular of charge holder

State Bank of Indore

Industrial Estate Branch, Pologround, Indore - 452016, Madhya Pradesh, India

sbn3016@sbindore.co.in

Nature of instrument creating charge

Recital Dates 29.03.2008 for Equitable Mortgage by deposit of title deeds

Date of instrument Creating the charge

29.03.2008

Amount secured by the charge

Rs.15.000 Millions

Brief of the principal terms an conditions and extent and operation of the charge

Rate of Interests:

2% above BPLR i.e. @ 13.50% p.a. floating

 

Terms of Repayment:

Repayable on Demand

 

Margin:

30% on Raw Materials

30% on Stock in Process

40% on Finished Goods

40% Stores and Spares, Packing Materials

50% on Book Debts

15% on Bank Guarantee/ LC Limit

 

Extent and Operation of the Charge:

First Charge on the current assets of the company to secure the various working capital limits

 

Fixed Assets:

 

 

Website Details:

 

Exports:

 

The Unit has been inspected by following Foreign Drug  Authority For Approval of Supply of Drug in their Countries.

 

 

The Unit has received the certificate of Appreciation in 1994 its Export Performance.

 

The Unit is Exporting 30 to 40 % of their Formulation directly and/or through Merchant Export to the following countries in own or Neutral Labels. Category of medicines being exported are Eye Drops, Dry Injections, Dry Syrup etc.

 

Ugabda, Republic of Yemen, Keneya, Tanzania, Turkey, Mauritius, United Arab Emirates, Nigeria, Germany, Liberia.

 

Newly Develop Countries "Indonesia, Thailand & Myanmar"

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                  None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.49.69

UK Pound

1

Rs.72.96

Euro

1

Rs.63.46

 

 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

5

PAID-UP CAPITAL

1~10

5

OPERATING SCALE

1~10

5

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

6

--PROFITABILIRY

1~10

4

--LIQUIDITY

1~10

5

--LEVERAGE

1~10

5

--RESERVES

1~10

5

--CREDIT LINES

1~10

5

--MARGINS

-5~5

-

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

45

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NR

In view of the lack of information, we have no basis upon which to recommend credit dealings

No Rating

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions